In addition to increasing urine glucose, reducing blood sugar, diuresis, and related hemodynamic effects, SGLT2i also has effects on myocardial metabolism, iontransporters, fibrosis, adipokines, and vascular function, thereby improving the prognosis of heart failure.[29,30] The results of the network meta-analysis showed that among the 4 interventions, the SGLT2i regimen had the best effect on the KCCQ score and NT-proBNP, and might be better than the ARNI regimen in reducing the rate of heart failure rehospitalization. This evidence concerns the gene NPPB and heart failure.